Christina Buchanan

Christina Buchanan

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2019 in Biomolecules
Verified
Journal Article
Open access
PDF file
CBChristina Buchanan
Christina Buchanan
KLKate Lee
Kate Lee
PSPeter R. Shepherd
Peter R. Shepherd
The hyper-activation of the phosphoinositide (PI) 3-kinase signaling pathway is a hallmark of many cancers and overgrowth syndromes, and as a result, there has been intense interest in the development of drugs that target the various isoforms of PI 3-kinase. Given the key role PI 3-kinases play in many normal cell functions, there is significant potential for the disruption of essential cellular functions by PI 3-kinase inhibitors in normal tissues; so-called on-target drug toxicity. It is, therefore, no surprise that progress within the clinical development of PI 3-kinase inhibitors as single-agent anti-cancer therapies has been slowed by the difficulty of identifying a therapeutic window. The aim of this review is to place the cellular, tissue and whole-body effects of PI 3-kinase inhibition in the context of understanding the potential for dose limiting on-target toxicities and to introduce possible strategies to overcome these.

5 November 2013 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
JDJames M. J. Dickson
James M. J. Dickson
WLWoo-Jeong Lee
Woo-Jeong Lee
PSPeter R. Shepherd
Peter R. Shepherd
CBChristina Buchanan
Christina Buchanan
NTT (N-terminal tags) on the catalytic (p110) sub-unit of PI 3-K (phosphoinositol 3-kinase) have previously been shown to increase cell signalling and oncogenic transformation. Here we test the impact of an NT (N-terminal) His-tag on in vitro lipid and protein kinase activity of all class-1 PI 3-K isoforms and two representative oncogenic mutant forms (E545K and H1047R), in order to elucidate the mechanisms behind this elevated signalling and transformation observed in vivo. Our results show that an NT His-tag has no impact on lipid kinase activity as measured by enzyme titration, kinetics and inhibitor susceptibility. Conversely, the NT His-tag did result in a differential effect on protein kinase activity, further potentiating the elevated protein kinase activity of both the helical domain and catalytic domain oncogenic mutants with relation to p110 phosphorylation. All other isoforms also showed elevated p110 phosphorylation (although not statistically significant). We conclude that the previously reported increase in cell signalling and oncogenic-like transformation in response to p110 NTT is not mediated via an increase in the lipid kinase activity of PI 3-K, but may be mediated by increased p110 autophosphorylation and/or other, as yet unidentified, intracellular protein/protein interactions. We further observe that tagged recombinant protein is suitable for use in in vitro lipid kinase screens to identify PI 3-K inhibitors; however, we recommend that in vivo (including intracellular) experiments and investigations into the protein kinase activity of PI 3-K should be conducted with untagged constructs.

22 June 2021 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
SPShilpan G. Patel
Shilpan G. Patel
CBChristina Buchanan
Christina Buchanan
EMEoin Mulroy
Eoin Mulroy
MSMark Simpson
Mark Simpson
HRHannah A. Reid
Hannah A. Reid
RRRichard H. Roxburgh
Richard H. Roxburgh

7 June 2013 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
CBChristina Buchanan
Christina Buchanan
ZPZhenzhen Peng
Zhenzhen Peng
ACAiko Cefre
Aiko Cefre
VSVijayalekshmi Sarojini
Vijayalekshmi Sarojini

1 April 2019 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
AGAnna C. Giddens
Anna C. Giddens
SGSwarna A. Gamage
Swarna A. Gamage
JKJackie D. Kendall
Jackie D. Kendall
WLWoo-Jeong Lee
Woo-Jeong Lee
BBBruce C. Baguley
Bruce C. Baguley
GRGordon W. Rewcastle
Gordon W. Rewcastle

5 October 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
KTKhanh B. Tran
Khanh B. Tran
SKSharada V. Kolekar
Sharada V. Kolekar
QWQian Wang
Qian Wang
JSJen-Hsing Shih
Jen-Hsing Shih
CBChristina Buchanan
Christina Buchanan
PSPeter R. Shepherd
Peter R. Shepherd
The fact that 10% of colorectal cancer tumors harbor BRAF V600E mutations suggested targeting BRAF as a potential therapy. However, BRAF inhibitors have only limited single-agent efficacy in this context. The potential for combination therapy has been shown by the BEACON trial where targeting the EGF receptor with cetuximab greatly increased efficacy of BRAF inhibitors in BRAF-mutant colorectal cancer. Therefore, we explored whether efficacy of the mutant BRAF inhibitor vemurafenib could be enhanced by cotargeting of either oncogenic WNT/β-catenin signaling or VEGFR signaling. We find the WNT/β-catenin inhibitors pyrvinium, ICG-001 and PKF118-310 attenuate growth of colorectal cancer cell lines in vitro with BRAF-mutant lines being relatively more sensitive. Pyrvinium combined with vemurafenib additively or synergistically attenuated growth of colorectal cancer cell lines in vitro. The selective and potent VEGFR inhibitor axitinib was most effective against BRAF-mutant colorectal cancer cell lines in vitro, but the addition of vemurafenib did not significantly increase these effects. When tested in vivo in animal tumor models, both pyrvinium and axitinib were able to significantly increase the ability of vemurafenib to attenuate tumor growth in xenografts of BRAF-mutant colorectal cancer cells. The magnitude of these effects was comparable with that induced by a combination of vemurafenib and cetuximab. This was associated with additive effects on release from tumor cells and tumor microenvironment cell types of substances that would normally aid tumor progression. Taken together, these preclinical data indicate that the efficacy of BRAF inhibitor therapy in colorectal cancer could be increased by cotargeting either WNT/β-catenin or VEGFRs with small-molecule inhibitors.